Mereo BioPharma and Sentynl Therapeutics sign licensing deal for alvelestat
Mereo BioPharma will be eligible for $40m in upfront and research and development payments, and up to $435m in milestones.
Drug Development
Alfasigma signs agreement to acquire Nordic Group
BeOne and Revolution Medicines partner for oncology therapies
Jazz Pharmaceuticals to acquire Actio Biosciences for $820m upfront
Innovent and Daiichi Sankyo sign deal for Vanflyta in China
Energenesis and Taiwan Tanabe to develop ENERGI-F703DFU for DFUs
Evotec and Odyssey collaborate on AI-enabled R&D
Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatments
